Drugs show efficacy in patients with type 2 diabetes, ESRD

02/1/2013 | Renal and Urology News

Sitagliptin therapy led to a 0.72% reduction in mean A1C levels at 54 weeks, while glipizide treatment resulted in an 0.87% decrease in type 2 diabetes patients with end-stage renal disease who require dialysis, according to a study in the American Journal of Kidney Diseases. Researchers also found the incidence rates of symptomatic hypoglycemia were 6.3% in the sitagliptin group and 10.8% in the glipizide group.

View Full Article in:

Renal and Urology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA